Narrative Summary of Selected Presentations given at the OM Pharma/Vifor Pharma URO-VAXOM® Summit, held in Buenos Aires, Argentina, on 26th–27th April 2014
Florian M.E. Wagenlehner,1 Matteo Bassetti,2 José Tirán-Saucedo,3 Kurt G. Naber4
1. Department of Urology, Paediatric Urology and Andrology of the Justus-Liebig-University, Giessen, Germany
2. Infectious Diseases Division, Santa Maria Misericordia University Hospital, Udine, Italy
3. Department of Obstetrics and Gynecology, Christus Muguerza-Conchita Hospital; Mexican Institute of Infectious Diseases in Obstetrics and Gynecology, Monterrey, Mexico
4. Technical University of Munich, Munich, Germany
Disclosure: The authors are global consultants of OM/Vifor Pharma Company, Meyrin, Switzerland.
Acknowledgements: Assistance was provided by Ewen Legg, ApotheCom ScopeMedical.
Support: The publication of this article was funded by OM/Vifor Pharma. The views and opinions ex- pressed are those of the authors and not necessarily those of OM/Vifor Pharma.
Citation: EMJ Urol. 2014;1(Suppl 2):3-13.
This educational summit, supported by an independent grant from OM/Vifor Pharma, brought together experts in the field of urology and gynaecology from Europe and Latin America to meet and discuss the cutting edge management of patients suffering from recurrent urinary tract infections (rUTIs). The meeting included plenary lectures as well as workshops and interactive sessions, allowing delegates and presenters to debate the most pressing international and local issues in the field.
The emergence and spread of antibiotic resistance (ABR) is a critical issue for global health and wellbeing. Due to its prevalence and empiric treatment with antibiotics, infection of the urinary tract represents one of the primary fronts in the battle against drug-resistant organisms. An understanding of the prevalence of uropathogens, their ABR, and effective guidelines based on this knowledge will be key in combating this global health threat.